Unclaimed brand
Houston-based clinical-stage company that develops multiple Treg-modulating therapies for neurodegenerative, autoimmune, and metabolic diseases.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#9C5726
Paarl
156, 87, 38
25, 61, 38
0, 44, 76, 39
#000F18
Swamp
0, 15, 24
203, 100, 5
100, 37, 0, 91
#A5E4FF
Anakiwa
165, 228, 255
198, 100, 82
35, 11, 0, 0
Coya Therapeutics is a Houston-based, clinical-stage biotechnology company developing proprietary therapies designed to enhance the function of regulatory T cells (Tregs). Its multi-modality research focuses on neurodegenerative, autoimmune, and metabolic diseases, with the company citing proof-of-concept data in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The pipeline includes Treg-enhancing biologics COYA 302 and COYA 301, allogeneic Treg-derived exosomes under the COYA 201 program, and autologous Treg cell therapy COYA 101.
These approaches reflect the company’s focus on developing different therapeutic modalities around Treg function. Coya is advancing clinical programs, including the ALSTARS Phase 2/3 trial of COYA 302 for ALS; the company reports enrollment across the United States and Canada. Its website provides information on its science and technology, clinical trials, pipeline, patient resources, and investor relations, alongside company news and updates.
Based in Houston, Coya Therapeutics also shares research announcements and trial information to keep patients, investors, and other audiences informed about its development efforts
Company type
Privately Held
Year founded
2020
Company size
2-10 employees
Regulatory T-cell biologics
Treg-derived exosome therapeutics
Autologous Treg cell therapy
ALS immunotherapy
Neuroinflammation drug development
